Education
About Us
Working with TipRanks
Follow Us
StemCell Institute (JP:7096)
:7096
RESEARCH TOOLSreports
Total Valuation
StemCell Institute has a market cap or net worth of ¥10.96B. The enterprise value is ¥16.43B.
Market Cap¥10.96B
Enterprise Value¥16.43B
Share Statistics
StemCell Institute has 10,246,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,246,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
StemCell Institute’s return on equity (ROE) is 0.15 and return on invested capital (ROIC) is 8.78%.
Return on Equity (ROE)0.15
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)8.78%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee27.34M
Profits Per Employee3.94M
Employee Count98
Asset Turnover0.36
Inventory Turnover19.36
Valuation Ratios
The current PE Ratio of StemCell Institute is 36.02. StemCell Institute’s PEG ratio is 1.47.
PE Ratio36.02
PS Ratio0.00
PB Ratio5.29
Price to Fair Value5.29
Price to FCF-1.37K
Price to Operating Cash Flow29.72
PEG Ratio1.47
Income Statement
In the last 12 months, StemCell Institute had revenue of 2.68B and earned 385.80M in profits. Earnings per share was 37.67.
Revenue2.68B
Gross Profit1.69B
Operating Income418.51M
Pretax Income565.71M
Net Income385.80M
EBITDA695.19M
Earnings Per Share (EPS)37.67
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
StemCell Institute pays an annual dividend of ¥25, resulting in a dividend yield of ―
Dividend Per Share¥25
Dividend Yield―
Payout Ratio66.37%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change-32.56%
50-Day Moving Average1.21K
200-Day Moving Average1.43K
Relative Strength Index (RSI)42.85
Average Volume (3m)49.66K
Important Dates
StemCell Institute upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend DateSep 27, 2024
Financial Position
StemCell Institute as a current ratio of 1.20, with Debt / Equity ratio of 19.75%
Current Ratio1.20
Quick Ratio1.19
Debt to Market Cap0.04
Net Debt to EBITDA-3.86
Interest Coverage Ratio348.18
Taxes
In the past 12 months, StemCell Institute has paid 179.92M in taxes.
Income Tax179.92M
Effective Tax Rate0.32
Enterprise Valuation
StemCell Institute EV to EBITDA ratio is 16.13, with an EV/FCF ratio of -1.11K.
EV to Sales4.19
EV to EBITDA16.13
EV to Free Cash Flow-1.11K
EV to Operating Cash Flow23.98
Balance Sheet
StemCell Institute has ¥3.53B in cash and marketable securities with ¥399.00M in debt, giving a net cash position of -¥3.13B billion.
Cash & Marketable Securities¥3.53B
Total Debt¥399.00M
Net Cash-¥3.13B
Net Cash Per Share-¥305.76
Tangible Book Value Per Share¥256.59
Margins
Gross margin is 63.16%, with operating margin of 15.62%, and net profit margin of 14.40%.
Gross Margin63.16%
Operating Margin15.62%
Pretax Margin21.12%
Net Profit Margin14.40%
EBITDA Margin25.95%
EBIT Margin21.16%
Analyst Forecast
The average price target for StemCell Institute is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast7.98%
EPS Growth Forecast24.12%